Save Evenity for High-Risk Women With Osteoporosis

June 2019

Evenity (ee-VEN-ih-tee, romosozumab) is the first med to increase bone growth AND decrease bone breakdown for postmenopausal osteoporosis.

Other osteoporosis meds do one or the other. For example, Forteo (teriparatide) and Tymlos (abaloparatide) build bone. Bisphosphonates (alendronate, etc) and Prolia (denosumab) slow bone breakdown.

Evenity is the first "sclerostin inhibitor." It's an injectable monoclonal antibody that blocks this protein involved in bone metabolism.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote